Drugs for dementia to be initiated by HPFT for commissioned services only. Transfer of care can take place for patients whose care is commissioned by HVCCG and ENHCCG in line with the prescribing support summary document for the management of dementia drugs process
Note: Orodispersible tablets and oral solution formulations are significantly more costly than standard tablet formulations and use of such formulations should be regularly reviewed and switched to standard tablets where possible and clinically appropriate.
|5mg and 10mg tablets
5mg and 10mg orodispersible tablets
|Orodispersible tablets only to be prescribed in those who cannot swallow solid dose forms
|8mg,16mg and 24mg MR (XL) capsules
4mg/ml oral solution
|MR/XL capsules more cost-effective than standard release tablets.
Oral solution only to be prescribed in those who cannot swallow solid dose forms.
5mg, 10mg,15mg and 20mg film coated tablets and orodispersible tablets
Titration pack containing 7 tablets of each strength 5mg, 10mg, 15mg, and 20mg film coated and orodispersible tablets
Memantine 10mg/ml oral solution*
Orodispersible tablets only to be prescribed in those who cannot swallow with solid dose forms.*Restricted use to associated dose administration errors. Only to be used when orodispersible tablets are unsuitable.
|1.5mg, 3mg, 4.5mg, 6mg capsules
4.6mg/24 hours, 9.5mg/24 hours and 13.3mg/24 hours patches
2mg/ml oral solution
|Oral solution is significantly more expensive than capsules or transdermal patches and should only be used when these formulations are not appropriate.